+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Alpha Mannosidosis Global Market Report 2024

  • PDF Icon

    Report

  • 200 Pages
  • February 2024
  • Region: Global
  • The Business Research Company
  • ID: 5939169
The alpha mannosidosis market size has grown rapidly in recent years. It will grow from $12.77 billion in 2023 to $15.26 billion in 2024 at a compound annual growth rate (CAGR) of 19.5%. The growth observed in the historical period can be attributed to several factors, including the expansion of emerging markets, urbanization trends, heightened demand for man-made fibers, and government initiatives supporting the textile industry.

The alpha mannosidosis market size is expected to see rapid growth in the next few years. It will grow to $29.62 billion in 2028 at a compound annual growth rate (CAGR) of 18.0%. The forecasted growth is fueled by global population growth, urbanization, e-commerce expansion, increased sportswear demand, and the rise of organized retail in developing economies, driven by social media penetration. Key trends include the growing use of enzyme therapy, adoption of hematopoietic stem cell transplantation, and the application of cisterna magna infusion.

The anticipated growth in the alpha mannosidosis market is expected to be driven by rising regulatory support for drug approval targeting rare diseases. The inherent challenge of conducting clinical trials for diseases with a small patient population is being addressed through regulatory initiatives. Notably, in 2021, the U.S. Food and Drug Administration (FDA) prioritized support for the development and evaluation of new treatments for rare diseases, recognizing the difficulties posed by limited patient populations. The FDA's authority to grant orphan drug designation for drugs addressing rare diseases provides sponsors with incentives such as tax credits for qualified clinical trials, exemption from user fees, and potential seven years of market exclusivity after approval. This regulatory backing is poised to propel the alpha mannosidosis market forward.

The growth of the alpha mannosidosis market is significantly influenced by the increasing healthcare expenditure. Healthcare expenditure encompasses costs related to family planning services, nutrition programs, emergency medical assistance, and health services. Government initiatives, grants, and incentives play a crucial role in providing financial support and encouraging research and development in the field of rare diseases, including alpha mannosidosis. For instance, data released by the Centers for Medicare & Medicaid Services (CMS) in June 2023 indicates that the national health expenditure (NHE) in the United States reached $4.3 trillion in 2021, accounting for 18.3% of the Gross Domestic Product (GDP). This growing healthcare expenditure reflects a commitment to supporting healthcare initiatives, contributing to the advancement of treatments for rare diseases. Consequently, the increasing healthcare expenditure is expected to drive the alpha mannosidosis market.

Major companies in the alpha mannosidosis market are actively focused on developing enzyme replacement therapies to address rare alpha-mannosidosis. Enzyme replacement therapy involves supplying exogenous alpha-mannosidase, which helps reduce the accumulation of mannose-rich oligosaccharides in various tissues and organs, a characteristic feature of alpha-mannosidosis contributing to its pathological effects. A notable example is Chiesi Global Rare Diseases, a U.S.-based pharmaceutical company, which, in February 2023, launched Lamzede (velmanase alfa), the first enzyme replacement therapy authorized in the United States for treating alpha-mannosidosis. Lamzede acts similarly to the human body's alpha-mannosidase enzyme, restoring normal cellular activity in patients. The treatment involves a weekly injection of 10 mg of Lamzede.

The alpha mannosidosis market is further propelled by a significant surge in biopharmaceutical research and development (R&D) investments. The emphasis on R&D reflects the commitment of pharmaceutical companies and academic institutions to advancing innovative treatments for alpha mannosidosis. Advancements in genetic therapies and a deeper understanding of the molecular basis of alpha mannosidosis have contributed to the development of potential treatments. Examples of increased R&D investments include the UK government's announcement of a spending of $18.9 billion (£15.3 billion) in pharmaceutical R&D in 2020, with an allocated budget of $49.2 billion (£39.8 billion) for 2022-2025. Moreover, in March 2023, Merck, a Germany-based biopharmaceuticals manufacturer, reported a 3.9% increase in R&D spending for the year 2022 compared to 2021. Similarly, Roche Holding AG, a Switzerland-based biopharmaceuticals manufacturer, announced a 3.7% increase in R&D expenditure for the year 2022 compared to 2021. These increased investments in research and development by biopharmaceutical companies underscore the momentum driving the alpha mannosidosis market forward.

In April 2023, Italian pharmaceutical company Chiesi Farmaceutici acquired Amryt Pharma, a UK-based pharmaceutical company, for $1.25 billion. This strategic acquisition enhances Chiesi's Global Rare Diseases business division by incorporating Amryt Pharma's approved commercial products for rare diseases into its existing portfolio. Amryt Pharma is recognized for its dedication to developing and delivering innovative treatments for rare diseases.

Major companies operating in the alpha mannosidosis market report are Chiesi Farmaceutici S.p.A., Cipla, EdiGene Inc., Immunochina, Takara Bio, Daiichi Sankyo Company, Ultragenyx Pharmaceutical Inc., Mitsubishi Tanabe Pharma, Oxford Biomedica PLC, Santen Pharmaceutical Co., Merck, GenScript, Cellular Biomedicine Group, GE Healthcare, Lonza, Nikon CeLL innovation Co. Ltd., Gilead Sciences, Bristol-Myers Squibb, Novartis AG, Amgen, Centogene, Zymenex A/S, Albumedix Ltd., Kite Pharma, Catalent, Freeline Therapeutics, Avectas, DiNAQOR AG, Vivet Therapeutics, Allergan, PsiOxus Therapeutics, Herantis Pharma PLC, Biocad, Celgene Corporation, Johnson & Johnson, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Bayer AG, Lyric Opera of Chicago, AMC Entertainment Holdings Inc., Regal Entertainment Group, Carmike Cinemas Inc., Ultragenyx, PTC Therapeutics, Gilead Sciences Inc., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Pfizer S.R.L., AstraZeneca PLC, Biotchpharma, Gene Vector Technologies, BrainStorm Cell Therapeutics, Pluristem, Biogen SA, Sanofi, Adcock Ingram.

North America was the largest region in the alpha mannosidosis market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alpha mannosidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the alpha mannosidosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The primary therapeutic approaches for alpha mannosidosis include bone marrow transplant (BMT) and enzyme replacement therapy (ERT). A bone marrow transplant involves replacing dysfunctional marrow with healthy marrow to address the underlying genetic defect. Enzyme replacement therapy aims to supplement or replace a deficient enzyme in individuals lacking the enzyme or having a deficiency. The indications for alpha mannosidosis are classified into Type I, Type II, and Type III, and these therapeutic interventions are implemented across various healthcare settings, including hospitals and specialty clinics. These treatments play a crucial role in managing the symptoms and addressing the underlying genetic abnormalities associated with alpha mannosidosis.

The alpha mannosidosis market research report is one of a series of new reports that provides alpha mannosidosis market statistics, including alpha mannosidosis industry global market size, regional shares, competitors with an alpha mannosidosis market share, detailed alpha mannosidosis market segments, market trends and opportunities, and any further data you may need to thrive in the alpha mannosidosis industry. This alpha mannosidosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The alpha mannosidosis market includes revenues earned by entities by intellectual disability, skeletal abnormalities, hearing loss, and muscle weakness. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.

Table of Contents

1. Executive Summary2. Alpha Mannosidosis Market Characteristics3. Alpha Mannosidosis Market Trends and Strategies
4. Alpha Mannosidosis Market - Macro Economic Scenario
4.1. Impact of High Inflation on the Market
4.2. Ukraine-Russia War Impact on the Market
4.3. COVID-19 Impact on the Market
5. Global Alpha Mannosidosis Market Size and Growth
5.1. Global Alpha Mannosidosis Market Drivers and Restraints
5.1.1. Drivers of the Market
5.1.2. Restraints of the Market
5.2. Global Alpha Mannosidosis Historic Market Size and Growth, 2018-2023, Value ($ Billion)
5.3. Global Alpha Mannosidosis Forecast Market Size and Growth, 2023-2028, 2033F, Value ($ Billion)
6. Alpha Mannosidosis Market Segmentation
6.1. Global Alpha Mannosidosis Market, Segmentation by Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Bone Marrow Transplant (BMT)
  • Enzyme Replacement Therapy (ERT)
  • Other Therapies
6.2. Global Alpha Mannosidosis Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Type I
  • Type II
  • Type III
6.3. Global Alpha Mannosidosis Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Specialty Clinics
7. Alpha Mannosidosis Market Regional and Country Analysis
7.1. Global Alpha Mannosidosis Market, Split by Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Alpha Mannosidosis Market, Split by Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8. Asia-Pacific Alpha Mannosidosis Market
8.1. Asia-Pacific Alpha Mannosidosis Market Overview
Region Information, Impact of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Alpha Mannosidosis Market, Segmentation by Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Alpha Mannosidosis Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Alpha Mannosidosis Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
9. China Alpha Mannosidosis Market
9.1. China Alpha Mannosidosis Market Overview
9.2. China Alpha Mannosidosis Market, Segmentation by Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Alpha Mannosidosis Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Alpha Mannosidosis Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
10. India Alpha Mannosidosis Market
10.1. India Alpha Mannosidosis Market, Segmentation by Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Alpha Mannosidosis Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Alpha Mannosidosis Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11. Japan Alpha Mannosidosis Market
11.1. Japan Alpha Mannosidosis Market Overview
11.2. Japan Alpha Mannosidosis Market, Segmentation by Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Alpha Mannosidosis Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Alpha Mannosidosis Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12. Australia Alpha Mannosidosis Market
12.1. Australia Alpha Mannosidosis Market, Segmentation by Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Alpha Mannosidosis Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Alpha Mannosidosis Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13. Indonesia Alpha Mannosidosis Market
13.1. Indonesia Alpha Mannosidosis Market, Segmentation by Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Alpha Mannosidosis Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Alpha Mannosidosis Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14. South Korea Alpha Mannosidosis Market
14.1. South Korea Alpha Mannosidosis Market Overview
14.2. South Korea Alpha Mannosidosis Market, Segmentation by Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Alpha Mannosidosis Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Alpha Mannosidosis Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15. Western Europe Alpha Mannosidosis Market
15.1. Western Europe Alpha Mannosidosis Market Overview
15.2. Western Europe Alpha Mannosidosis Market, Segmentation by Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Alpha Mannosidosis Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Alpha Mannosidosis Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16. UK Alpha Mannosidosis Market
16.1. UK Alpha Mannosidosis Market, Segmentation by Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Alpha Mannosidosis Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Alpha Mannosidosis Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17. Germany Alpha Mannosidosis Market
17.1. Germany Alpha Mannosidosis Market, Segmentation by Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Alpha Mannosidosis Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Alpha Mannosidosis Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18. France Alpha Mannosidosis Market
18.1. France Alpha Mannosidosis Market, Segmentation by Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Alpha Mannosidosis Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Alpha Mannosidosis Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19. Italy Alpha Mannosidosis Market
19.1. Italy Alpha Mannosidosis Market, Segmentation by Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Alpha Mannosidosis Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Alpha Mannosidosis Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20. Spain Alpha Mannosidosis Market
20.1. Spain Alpha Mannosidosis Market, Segmentation by Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Alpha Mannosidosis Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Alpha Mannosidosis Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21. Eastern Europe Alpha Mannosidosis Market
21.1. Eastern Europe Alpha Mannosidosis Market Overview
21.2. Eastern Europe Alpha Mannosidosis Market, Segmentation by Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Alpha Mannosidosis Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Alpha Mannosidosis Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22. Russia Alpha Mannosidosis Market
22.1. Russia Alpha Mannosidosis Market, Segmentation by Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Alpha Mannosidosis Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Alpha Mannosidosis Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23. North America Alpha Mannosidosis Market
23.1. North America Alpha Mannosidosis Market Overview
23.2. North America Alpha Mannosidosis Market, Segmentation by Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Alpha Mannosidosis Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Alpha Mannosidosis Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24. USA Alpha Mannosidosis Market
24.1. USA Alpha Mannosidosis Market Overview
24.2. USA Alpha Mannosidosis Market, Segmentation by Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Alpha Mannosidosis Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Alpha Mannosidosis Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25. Canada Alpha Mannosidosis Market
25.1. Canada Alpha Mannosidosis Market Overview
25.2. Canada Alpha Mannosidosis Market, Segmentation by Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Alpha Mannosidosis Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Alpha Mannosidosis Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26. South America Alpha Mannosidosis Market
26.1. South America Alpha Mannosidosis Market Overview
26.2. South America Alpha Mannosidosis Market, Segmentation by Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Alpha Mannosidosis Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Alpha Mannosidosis Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27. Brazil Alpha Mannosidosis Market
27.1. Brazil Alpha Mannosidosis Market, Segmentation by Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Alpha Mannosidosis Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Alpha Mannosidosis Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28. Middle East Alpha Mannosidosis Market
28.1. Middle East Alpha Mannosidosis Market Overview
28.2. Middle East Alpha Mannosidosis Market, Segmentation by Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Alpha Mannosidosis Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Alpha Mannosidosis Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29. Africa Alpha Mannosidosis Market
29.1. Africa Alpha Mannosidosis Market Overview
29.2. Africa Alpha Mannosidosis Market, Segmentation by Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Alpha Mannosidosis Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Alpha Mannosidosis Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
30. Alpha Mannosidosis Market Competitive Landscape and Company Profiles
30.1. Alpha Mannosidosis Market Competitive Landscape
30.2. Alpha Mannosidosis Market Company Profiles
30.2.1. Chiesi Farmaceutici S.p.A.
30.2.1.1. Overview
30.2.1.2. Products and Services
30.2.1.3. Strategy
30.2.1.4. Financial Performance
30.2.2. Cipla
30.2.2.1. Overview
30.2.2.2. Products and Services
30.2.2.3. Strategy
30.2.2.4. Financial Performance
30.2.3. EdiGene Inc.
30.2.3.1. Overview
30.2.3.2. Products and Services
30.2.3.3. Strategy
30.2.3.4. Financial Performance
30.2.4. Immunochina
30.2.4.1. Overview
30.2.4.2. Products and Services
30.2.4.3. Strategy
30.2.4.4. Financial Performance
30.2.5. Takara Bio
30.2.5.1. Overview
30.2.5.2. Products and Services
30.2.5.3. Strategy
30.2.5.4. Financial Performance
31. Alpha Mannosidosis Market Other Major and Innovative Companies
31.1. Daiichi Sankyo Company
31.2. Ultragenyx Pharmaceutical Inc
31.3. Mitsubishi Tanabe Pharma
31.4. Oxford Biomedica plc
31.5. Santen Pharmaceutical Co.
31.6. Merck
31.7. GenScript
31.8. Cellular Biomedicine Group
31.9. GE Healthcare
31.10. Lonza
31.11. Nikon CeLL innovation Co. Ltd.
31.12. Gilead Sciences
31.13. Bristol-Myers Squibb
31.14. Novartis AG
31.15. Amgen
32. Global Alpha Mannosidosis Market Competitive Benchmarking33. Global Alpha Mannosidosis Market Competitive Dashboard34. Key Mergers and Acquisitions in the Alpha Mannosidosis Market
35. Alpha Mannosidosis Market Future Outlook and Potential Analysis
35.1 Alpha Mannosidosis Market in 2028 - Countries Offering Most New Opportunities
35.2 Alpha Mannosidosis Market in 2028 - Segments Offering Most New Opportunities
35.3 Alpha Mannosidosis Market in 2028 - Growth Strategies
35.3.1 Market Trend-based Strategies
35.3.2 Competitor Strategies
36. Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic and Forecast Inflation Rates
36.4. Research Inquiries
36.5. About the Analyst
36.6. Copyright and Disclaimer

Executive Summary

Alpha Mannosidosis Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on alpha mannosidosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
  • Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for alpha mannosidosis? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
  • The impact of higher inflation in many countries and the resulting spike in interest rates.
  • The continued but declining impact of COVID-19 on supply chains and consumption patterns.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Report Scope

Markets Covered:
1) By Therapy Type: Bone Marrow Transplant (BMT); Enzyme Replacement Therapy (ERT); Other Therapies
2) By Indication: Type I; Type II; Type III
3) By End-user: Hospitals; Specialty Clinics

Key Companies Mentioned: Chiesi Farmaceutici S.p.A.; Cipla; EdiGene Inc.; Immunochina; Takara Bio

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes

Delivery Format: PDF, Word and Excel Data Dashboard

Companies Mentioned

  • Chiesi Farmaceutici S.p.A.
  • Cipla
  • EdiGene Inc.
  • Immunochina
  • Takara Bio
  • Daiichi Sankyo Company
  • Ultragenyx Pharmaceutical Inc
  • Mitsubishi Tanabe Pharma
  • Oxford Biomedica plc
  • Santen Pharmaceutical Co.
  • Merck
  • GenScript
  • Cellular Biomedicine Group
  • GE Healthcare
  • Lonza
  • Nikon CeLL innovation Co. Ltd.
  • Gilead Sciences
  • Bristol-Myers Squibb
  • Novartis AG
  • Amgen
  • Centogene
  • Zymenex A/S
  • Albumedix Ltd
  • Kite Pharma
  • Catalent
  • Freeline Therapeutics
  • Avectas
  • DiNAQOR AG
  • Vivet Therapeutics
  • Allergan
  • PsiOxus Therapeutics
  • Herantis Pharma Plc
  • Biocad
  • Celgene Corporation
  • Johnson & Johnson
  • F. Hoffmann-La Roche Ltd
  • Eli Lilly and Company
  • Bayer AG
  • Lyric Opera of Chicago
  • AMC Entertainment Holdings Inc
  • Regal Entertainment Group
  • Carmike Cinemas Inc
  • Ultragenyx
  • PTC Therapeutics
  • Gilead Sciences Inc.
  • GlaxoSmithKline plc
  • Takeda Pharmaceutical Company Limited
  • Pfizer S.R.L.
  • AstraZeneca plc
  • Biotchpharma
  • Gene Vector Technologies
  • BrainStorm Cell Therapeutics
  • Pluristem
  • Biogen SA
  • Sanofi
  • Adcock Ingram

Methodology

Loading
LOADING...

Table Information